Royal College of Psychiatrists. Consensus Statement on High-Dose Antipsychotic Medication (Council Report CR138). Royal College of Psychiatrists, 2006.
Harrington, M, Lelliott, C, Paton, C, Okocha, C, Duffett, R, Sensky, T.
The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatr Bull
2002; 26: 414–8.
Keks, NA, Alston, K, Hope, J, Krapivensky, N, Culhane, C, Tanaghow, A, et al.
Use of antipsychotics and adjunctive medications by inner urban community psychiatric service. Aust N Z J Psychiatry
1999; 33: 896–901.
Ito, C, Kubota, Y, Sato, M.
A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci
1999; 53 (suppl): S35–40.
Ito, H, Koyama, A, Higuchi, T.
Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry
2005; 187: 243–7.
Taylor, M, Shajahan, P, Lawrie, SM. Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry
2008; 69: 240–5.
Tungaraza, TE, Gupta, S, Jones, J, Poole, R, Slegg, G.
Polypharmacy and high-dose antipsychotic regimes in the community. Psychiatrist
2010; 34: 44–6.
Grech, P, Taylor, D.
Long-term antipsychotic polypharmacy: how does it start, why does it continue?
Therapeutic Advances in Psychopharmacology
2012; 2: 5–11.
Antipsychotic polypharmacy – confusion reigns. Psychiatrist
2010; 34: 41–3.
Fleischhacker, WW, Heikkinen, T, Olie, JP, Landsberg, W, Dwaele, P, McQuade, RD, et al.
Weight change on aripiprazole–clozapine combination in schizophrenic patients with weight gain and suboptimal response on clozapine: 16-week double-blind study. Eur Psychiatry
2008; 2 (suppl 23): s114–5.
Shim, JC, Shin, JG, Kelly, DL, Jung, DU, Seo, YS, Liu, KH
Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo controlled trail. Am J Psychiatry
2007; 164: 1404–10.
Josiassen, RC, Joseph, A, Kohegyi, E, Stokes, S, Dadvand, M, Paing, WW, et al.
Clozapine augmented with risperidone in the treatment of schizophrenia: a randomised, double-blind, placebo-controlled trial. Am J Psychiatry
2005; 162: 130–6.
Shiloh, R, Zemishlany, Z, Aizenberg, D, Radwan, M, Schwartz, B, Dorfman-Etrog, P, et al.
Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry
1997; 171: 569–73.
Langan, J, Shajahan, P.
Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist
2010; 34: 58–62.
National Collaborating Centre for Mental Health. Schizophrenia: The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Updated Edition). British Psychological Society and Royal College of Psychiatrists, 2010.
Royal Pharmaceutical Society of Great Britain, British Medical Association. British National Formulary 56. BMJ Books & Pharmaceuticals Press, 2008.
Taylor, D, Paton, C, Kapur, S.
The Maudsley Prescribing Guidelines (10th edn). Informa Healthcare, 2009.
NHS Greater Glasgow and Clyde Health Board. High Dose Antipsychotic Therapy Guideline. NHS Greater Glasgow and Clyde, 2008.
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
Yorston, G, Pinney, A.
Use of high dose antipsychotic medication. Psychiatr Bull
1997; 21: 566–9.
NHS Quality Improvement Scotland. Standards for Integrated Care Pathways for Mental Health. NHS Quality Improvement Scotland, 2007.
Howes, OD, Vergunst, F, Gee, S, McGuire, P, Kapur, S, Taylor, D.
Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry
2012; 201: 481–5.
Paton, C, Barnes, TRE, Cavanagh, M-R, Taylor, D, Lelliott, P.
High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n prescribing. Br J Psychiatry
2008; 192: 435–9.
Tyson, PJ, Mortimer, AM, Wheeler, JA. High-dose antipsychotic treatment in clinical practice. A review, audit and survey of consultant psychiatrist opinions. Psychiatr Bull
1999; 23: 661–4.
Geddes, JR, Freemantle, N, Harrison, P, Bebbington, PE. Atypical antipsychotics in the treatment of schizophrenia – systematic review and meta-regression analysis. BMJ
2000; 321: 1371–6.
Waddington, JL, Youssef, HA, Kinsella, A.
Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry
1998; 173: 325–9.
Curkendall, SM, Mo, J, Glasser, DB, Rose Stang, M, Jones, JK. Cardiovascular disease in patients with schizophrenia in Saskatchwan, Canada. J Clin Psychiatry
2004; 65: 715–20.
Barnes, TRE, Paton, C.
Role of the Prescribing Observatory for Mental Heath. Br J Psychiatry
2012; 201: 428–9.